Current therapy for malignant mesothelioma

Current Oncology Reports

Volumn 4, Issue 4, 2002, Pages 305-313

  Smythe, W Roy ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Intensity Modulate Radiation Therapy; Malignant Mesothelioma; Malignant Pleural Mesothelioma; Mesothelioma Cell; Pemetrexed

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE;

ADJUVANT THERAPY; ASBESTOSIS; HUMAN; MESOTHELIOMA; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PLEURA TUMOR; PROGNOSIS; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME;

ANTIMETABOLITES, ANTINEOPLASTIC; ASBESTOSIS; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; HUMANS; MESOTHELIOMA; PLEURAL NEOPLASMS; PROGNOSIS; RADIOTHERAPY, ADJUVANT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0036652180     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-002-0006-2     Document Type: Article

References (81)

1. Peto J, Hodgson JT, Matthews FE, Jones JR: Continuing increase in mesothelioma mortality in Britain. Lancet 1995, 345:535–539. DOI: 10.1016/S0140-6736(95)90462-X
2. Testa JR, Carbone M, Hirvonen A, et al.: A multi-institutional study confirms the presence and expression of simian virus 40 in human malignant mesotheliomas. Cancer Res 1998, 58:4505–4509.
3. Kawai A, Nagasaka Y, Muraki M, et al.: Brain metastasis in malignant pleural mesothelioma. Intern Med 1997, 36:591–594.
4. Ruiz HG, Garcia GT, Azagra RP, et al.: Pelvic and lumbar metastasis detected by bone scintigraphy in malignant pleural mesothelioma. Nuklearmedizin 1999, 38:68–71.
5. Baas P, van Meerbeeck J, Groen H, et al.: Caelyx (TM) in malignant mesothelioma: a phase II EORTC study. Ann Oncol 2000, 11:697–700. DOI: 10.1023/A:1008346925273
6. Lerner HJ, Schoenfeld DA, Martin A, et al.: Malignant mesothelioma: the Eastern Cooperative Oncology Group (ECOG) experience. Cancer 1983, 52:1981–1985. DOI: 10.1002/1097-0142(19831201)52:11<1981::AID-CNCR2820521102>3.0.CO;2-P
7. Colbert N, Vannetzel JM, Izrael V, et al.: A prospective study of detorubicin in malignant mesothelioma. Cancer 1985, 56:2170–2174. DOI: 10.1002/1097-0142(19851101)56:9<2170::AID-CNCR2820560905>3.0.CO;2-L
8. Kindler HL, van Meerbeeck JP: The role of gemcitabine in the treatment of malignant mesothelioma. Semin Oncol 2002, 29:70–76. DOI: 10.1053/sonc.2002.30232
9. van Meerbeeck JP, Bass P, Debruyne C, et al.: A phase II study of gemcitabine in patients with malignant pleural mesothelioma. Cancer 1999, 85:2577–2582. DOI: 10.1002/(SICI)1097-0142(19990615)85:12<2577::AID-CNCR13>3.0.CO;2-S
10. Bischoff HG, Manegold C, Knopp M, et al.: Gemcitabine may reduce tumor load and tumor associated symptoms in malignant pleural mesothelioma. [abstract]. Proc ASCO 1998, 17:464a.
11. Baas P: Chemotherapy for malignant mesothelioma: from doxorubicin to vinorelbine. Semin Oncol 2002, 29:62–69. DOI: 10.1053/sonc.2002.30231
12. Mbidde EK, Smith IE, Harland S: Phase II trial of carboplatin (Jm8) in the treatment of patients with mesothelioma (M). Br J Cancer 1986, 54:215–216.
13. Vogelzang NJ, Goutsou M, Corson JM, et al.: Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B. Cancer Chemother Pharmacol 1990, 27:239–242. DOI: 10.1007/BF00685720
14. Steele JP, John W, Vogelzang NJ: Phase II trial of vinorelbine and oxaliplatin in malignant pleural mesothelioma [abstract]. Proc ASCO 1999, 18:1844a.
15. Fizazi K, John WJ, Vogelzang NJ: The emerging role of antifolates in the treatment of malignant pleural mesothelioma. Semin Oncol 2002, 29:77–81. DOI: 10.1053/sonc.2002.30233
16. Umsawasdi T, Dhingra HM, Charnsangavej C, Luna MA: A case report of malignant pleural mesothelioma with long-term disease control after chemotherapy. Cancer 1991, 67:48–54. DOI: 10.1002/1097-0142(19910101)67:1<48::AID-CNCR2820670110>3.0.CO;2-I
17. Colleoni M, Liessi G, Avventi C, et al.: Response to chemotherapy of brain metastases from malignant pleural mesothelioma. Tumori 1996, 82:456–458.
18. Dimitrov NV, Egner J, Balcueva E, Suhrland LG: High-dose methotrexate with citrovorum factor and vincristine in the treatment of malignant mesothelioma. Cancer 1982, 50:1245–1247. DOI: 10.1002/1097-0142(19821001)50:7<1245::AID-CNCR2820500704>3.0.CO;2-H
19. Djerassi I, Kim JS, Reggev A: Response of astrocytoma to highdose methotrexate with citrovorum factor rescue. Cancer 1985, 55:2741–2747. DOI: 10.1002/1097-0142(19850615)55:12<2741::AID-CNCR2820551202>3.0.CO;2-2
20. Solheim OP, Saeter G, Finnanger AM, Stenwig AE: High-dose methotrexate in the treatment of malignant mesothelioma of the pleura: a phase II study. Br J Cancer 1992, 65:956–960.
21. Vogelzang NJ, Weissman LB, Herndon JE, et al.: Trimetrexate in malignant mesothelioma: a Cancer and Leukemia Group B phase II study. J Clin Oncol 1994, 12:1436–1442.
22. Kindler HL, Belani CP, Herndon JE, et al.: Edatrexate (10-ethyldeaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma: sequential phase II trials by the Cancer and Leukemia Group B. Cancer 1999, 86:1985–1991. DOI: 10.1002/(SICI)1097-0142(19991115)86:10<1985::AID-CNCR15>3.0.CO;2-H
23. Halme M, Knuuttila A, Vehmas T, et al.: High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma. Br J Cancer 1999, 80:1781–1785. DOI: 10.1038/sj.bjc.6690597
24. Brodin O, Knuuttila A, Halme H: Combined treatment of malignant mesothelioma of the pleura with high dose methotrexate and interferon alfa and gamma [abstract]. Br J Cancer 1999, 80:1781–1985. DOI: 10.1038/sj.bjc.6690597
25. Upham JW, Musk AW, van-Hagel G: Interferon alpha and doxorubicin in malignant mesothelioma: a phase II study. Aust NZ J Med 1993, 2316:683–687.
26. Carmichael J, Degraff WG, Gamson J, et al.: Radiation sensitivity of human lung cancer cell lines. Eur J Cancer Clin Oncol 1989, 25:527–534. DOI: 10.1016/0277-5379(89)90266-6
27. Boutin C, Rey F, Viallat JR: Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma: a randomized trial of local radiotherapy. Chest 1995, 108:754–758.
28. Kutcher GJ, Kestler C, Greenblatt D, et al.: Technique for external beam treatment for mesothelioma. Int J Radiat Oncol Biol Physics 1987, 13:1747–1752.
29. Sauter ER, Langer C, Coia LR, et al.: Optimal management of malignant mesothelioma after subtotal pleurectomy: revisiting the role of intrapleural chemotherapy and postoperative radiation. J Surg Oncol 1995, 60:100–105. DOI: 10.1002/jso.2930600207
30. Soubra M, Dunscombe PB, Hodson DI, Wong G: Physical aspects of external beam radiotherapy for the treatment of malignant pleural mesothelioma. Int J Radiat Oncol Biol Physics 1990, 18:1521–1527.
31. Baldini EH, Recht A, Strauss GM, et al.: Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 1997, 63:334–338. DOI: 10.1016/S0003-4975(96)01228-3
32. Rusch V, Saltz L, Venkatraman E, et al.: A phase II trial of pleurectomy/ decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. J Clin Oncol 1994, 12:1156–1163.
33. Rusch VW, Rosenzweig K, Venkatraman E, et al.: A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001, 122:788–795. This MSKCC study demonstrated the potential efficacy of radiotherapy. DOI: 10.1067/mtc.2001.116560
34. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al.: Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999, 117:54–63. This landmark paper demonstrated improved survival in patients with epithelial histology, negative mediastinal nodes, and complete surgical resection. DOI: 10.1016/S0022-5223(99)70469-1
35. Eisbruch A, Ten Haken RK, Kim HM, et al.: Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. Int J Radiat Oncol Biol Physics 1999, 45:577–587. One of two important trials of intensity-modulated radiotherapy. DOI: 10.1016/S0360-3016(99)00247-3
36. Zelefsky MJ, Fuks Z, Happersett L, et al.: Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol 2000, 55:241–249. One of two important trials of intensity-modulated radiotherapy. DOI: 10.1016/S0167-8140(99)00100-0
37. Ahamad A, Forster R, Smythe R, et al.: IMRT for adjuvant treatment of malignant mesothelioma [abstract]. American Society of Therapeutic Radiology and Oncology, San Francisco, 2001.
38. Noppen M, DeGreve J, Mignolet M, Vincken W: A prospective, randomised study comparing the efficacy of talc slurry and bleomycin in the treatment of malignant pleural effusions. Acta Clinica Belgica 1997, 52:258–262.
39. Senyigit A, Yaramis A, Gurkan F, et al.: Pulmonary alveolar microlithiasis: a rare familial inheritance with report of six gases in a family: contribution of six new cases to the number of case reports in Turkey. Respiration 2001, 68:204–209. DOI: 10.1159/000050494
40. Nasreen N, Mohammed KA, Dowling PA, et al.: Talc induces apoptosis in human malignant mesothelioma cells in vitro. Am J Respir Crit Care Med 2000, 161:595–600.
41. Merritt N, Blewett C, Miller JD, et al.: Survival after conservative (palliative) management of pleural malignant mesothelioma. J Surg Oncol 2001, 78:171–174. DOI: 10.1002/jso.1143
42. Martin-Ucar AE, Edwards JG, Rengajaran A, et al.: Palliative surgical debulking in malignant mesothelioma: predictors of survival and symptom control. Eur J Cardiothorac Surg 2001, 20:1117–1121. DOI: 10.1016/S1010-7940(01)00995-2
43. Rusch VW: Pleurectomy/decortication and adjuvant therapy for malignant mesothelioma. Chest 1993, 103:S382-S384. DOI: 10.1378/chest.103.4_Supplement.382S
44. Rusch VW, Piantadosi S, Holmes EC: The role of extrapleural pneumonectomy in malignant pleural mesothelioma: a Lung Cancer Study Group Trial. J Thorac Cardiovasc Surg 1991, 102:1–9.
45. Butchart EG, Ashcroft T, Barnsley WC, Holden MP: Pleuropneumonectomy in management of diffuse malignant mesothelioma of pleura: experience with 29 patients. Thorax 1976, 31:15–24.
46. Rusch VW, Venkatraman ES: Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann Thorac Surg 1999, 68:1799–1804. The mortality rate in this study proved to be lower than expected. DOI: 10.1016/S0003-4975(99)01038-3
47. Rusch V, Saltz L, Venkatraman E, et al.: A phase II trial of pleurectomy/ decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. J Clin Oncol 1994, 12:1156–1163.
48. Rice TW, Adelstein DJ, Kirby TJ, et al.: Aggressive multimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 1994, 58:24–29. DOI: 10.1016/0003-4975(94)91066-9
49. Juturi J, Adelstein DJ, Rice tea: intracavitary paclitaxel in the multimodality management of malignant pleural mesothelioma [abstract]. Proc ASCO 2001, 20:366a.
50. Ratto GB, Civalleri D, Esposito M, et al.: Pleural space perfusion with cisplatin in the multimodality treatment of malignant mesothelioma: a feasibility and pharmacokinetic study. J Thorac Cardiovasc Surg 1999, 117:759–765. DOI: 10.1016/S0022-5223(99)70297-7
51. Zellos LS, Sugarbaker DJ: Multimodality treatment of diffuse malignant pleural mesothelioma. Semin Oncol 2002, 29:41–50. DOI: 10.1053/sonc.2002.30230
52. Pass HI, Temeck BK, Kranda K, et al.: Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma. Ann Surg Oncol 1997, 4:628–633. DOI: 10.1007/BF02303746
53. Moskal TL, Dougherty TJ, Urschel JD, et al.: Operation and photodynamic therapy for pleural mesothelioma: 6-year follow-up. Ann Thorac Surg 1998, 66:1128–1133. DOI: 10.1016/S0003-4975(98)00799-1
54. Sandberg AA, Bridge JA: Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: mesothelioma. Cancer Genet Cytogenet 2001, 127:93–110. DOI: 10.1016/S0165-4608(01)00432-0
55. Kettunen E, Nissen AM, Ollikainen T, et al.: Gene expression profiling of malignant mesothelioma cell lines: cDNA array study. Int J Cancer 2001, 91:492–496. DOI: 10.1002/1097-0215(200002)9999:9999<::AID-IJC1094>3.0.CO;2-M
56. Sun X, Dobra K, Bjornstedt M, Hjerpe A: Upregulation of 9 genes, including that for thioredoxin, during epithelial differentiation of mesothelioma cells. Differentiation 2000, 66:181–188. DOI: 10.1046/j.1432-0436.2000.660404.x
57. Ascoli V, Aalto Y, Carnovale-Scalzo C, et al.: DNA copy number changes in familial malignant mesothelioma. Cancer Genet Cytogenet 2001, 127:80–82. DOI: 10.1016/S0165-4608(00)00420-9
58. Taguchi T, Jhanwar SC, Siegfried JM, et al.: Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma. Cancer Res 1993, 53:4349–4355.
59. Cheng JQ, Jhanwar SC, Klein WM, et al.: p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 1994, 54:5547–5551.
60. Strickler HD: A multicenter evaluation of assays for detection of SV40 DNA and results in masked mesothelioma specimens. Cancer Epidemiol Biomarkers Prev 2001, 10:523–532.
61. Cicala C, Pompetti F, Carbone M: SV40 induces mesotheliomas in hamsters. Am J Pathol 1993, 142:1524–1533.
62. Smythe WR, Hwang HC, Amin KM, et al.: Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: an effective in vitro drug sensitization system. Cancer Res 1994, 54:2055–2059.
63. Smythe WR, Hwang HC, Elshami AA, et al.: Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene. Ann Surg 1995, 222:78–86. DOI: 10.1097/00000658-199507000-00013
64. Sterman DH, Treat J, Litzky LA, et al.: Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 1998, 9:1083–1092. The first clinical trial using a gene therapy approach for mesothelioma.
65. Frizelle SP, Rubins JB, Zhou JX, et al.: Gene therapy of established mesothelioma xenografts with recombinant p16INK4a adenovirus. Cancer Gene Ther 2000, 7:1421–1425. DOI: 10.1038/sj.cgt.7700241
66. Pataer A, Smythe WR, Yu R, et al.: Adenovirus-mediated bak gene transfer induces apoptosis in mesothelioma cell lines. J Thorac Cardiovasc Surg 2001, 121:61–67. DOI: 10.1067/mtc.2001.111419
67. Huang DC, Cory S, Strasser A: Bcl-2, Bcl-XL and adenovirus protein E1B19kD are functionally equivalent in their ability to inhibit cell death. Oncogene 1997, 14:405–414. DOI: 10.1038/sj.onc.1200848
68. Narasimhan SR, Yang L, Gerwin BI, Broaddus VC: Resistance of pleural mesothelioma cell lines to apoptosis: relation to expression of Bcl-2 and Bax. Am J Physiol 1998, 275:L165-L171.
69. Segers K, Ramael M, Singh SK, et al.: Immunoreactivity for bcl-2 protein in malignant mesothelioma and non-neoplastic mesothelium. Virchows Arch 1994, 424:631–634. DOI: 10.1007/BF01069743
70. Leech SH, Olie RA, Gautschi O, et al.: Induction of apoptosis in lung-cancer cells following bcl-xL anti-sense treatment. Int J Cancer 2000, 86:570–576. DOI: 10.1002/(SICI)1097-0215(20000515)86:4<570::AID-IJC20>3.0.CO;2-T
71. Schmitt E, Sane AT, Steyaert A, et al.: The Bcl-xL and Bax-alpha control points: modulation of apoptosis induced by cancer chemotherapy and relation to TPCK-sensitive protease and caspase activation. Biochem Cell Biol 1997, 75:301–314. DOI: 10.1139/bcb-75-4-301
72. Cao XX, Mohiuddin I, Ece F, et al.: Histone deacetylase inhibitor down-regulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma. Am J Respir Cell Mol Biol 2001, 25:562–568.
73. Mohiuddin I, Cao X, Fang B, et al.: Significant augmentation of pro-apoptotic gene therapy by pharmacologic bcl-xl downr-regulation in mesothelioma. Cancer Gene Ther 2001, 8:547–554. DOI: 10.1038/sj.cgt.7700332
74. Smythe WR, Mohiuddin I, Cao X, Ozvaran M: Antisense therapy for malignant mesothelioma utilizing antisense oligonucleotides targeting the Bclxl gene product. J Thorac Cardiovasc Surg 2002, in press.
75. Waheed I, Guo ZS, Chen GA, et al.: Antisense to SV40 early gene region induces growth arrest and apoptosis in T-antigen-positive human pleural mesothelioma cells. Cancer Res 1999, 59:6068–6073.
76. Leigh RA, Webster I: Lymphocytic infiltration of pleural mesothelioma and is significance for survival. S Afr Med J 1982, 61:1007–1009.
77. Haslam PL, Lukoszek A, Merchant JA, Turnerwarwick M: Lymphocyte responses to phytohemagglutinin in patients with asbestosis and pleural mesothelioma. Clin Exper Immunol 1978, 31:178–188.
78. Manning LS, Davis MR, Robinson BWS: Asbestos fibers inhibit the in vitro activity of lymphokine-activated killer (Lak) cells from healthy individuals and patients with malignant mesothelioma. Clin Exper Immunol 1991, 83:85–91. DOI: 10.1111/j.1365-2249.1991.tb05593.x
79. Boutin C, Nussbaum E, Monnet I, et al.: Intrapleural treatment with recombinant gamma-interferon in early-stage malignant pleural mesothelioma. Cancer 1994, 74:2460–2467. This trial deserves special mention for its demonstration of a 20% response rate with intrapleural interferon gamma, including eight complete responses in 89 patients. DOI: 10.1002/1097-0142(19941101)74:9<2460::AID-CNCR2820740912>3.0.CO;2-N
80. Robinson BWS, Bowman RV, Manning LS, et al.: Interleukin-2 and lymphokine activated killer cells in malignant pleural mesothelioma. Eur Respir Rev 1993, 3:220–222.
81. Scagliotti G, Shin D, Kindler H, et al.: Phase II study of ALIMTA (pemetrexed disodium, MTA) single agent in patients with malignant pleural mesothelioma [abstract]. Eur J Cancer 2001, 37:20. DOI: 10.1016/S0959-8049(01)80558-X